CN112424608A - 用于疾病的预后和管理的方法 - Google Patents

用于疾病的预后和管理的方法 Download PDF

Info

Publication number
CN112424608A
CN112424608A CN201980045566.7A CN201980045566A CN112424608A CN 112424608 A CN112424608 A CN 112424608A CN 201980045566 A CN201980045566 A CN 201980045566A CN 112424608 A CN112424608 A CN 112424608A
Authority
CN
China
Prior art keywords
als
subject
biomarker
scd14
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980045566.7A
Other languages
English (en)
Chinese (zh)
Inventor
斯坦利·H·阿佩尔
大卫·R·比尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Methodist Hospital
Original Assignee
Methodist Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Methodist Hospital filed Critical Methodist Hospital
Publication of CN112424608A publication Critical patent/CN112424608A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980045566.7A 2018-05-10 2019-05-10 用于疾病的预后和管理的方法 Pending CN112424608A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669915P 2018-05-10 2018-05-10
US62/669,915 2018-05-10
PCT/US2019/031858 WO2019217916A1 (en) 2018-05-10 2019-05-10 Methods for prognosis and management of disease

Publications (1)

Publication Number Publication Date
CN112424608A true CN112424608A (zh) 2021-02-26

Family

ID=66655475

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045566.7A Pending CN112424608A (zh) 2018-05-10 2019-05-10 用于疾病的预后和管理的方法

Country Status (8)

Country Link
US (1) US20210231686A1 (https=)
EP (1) EP3791188A1 (https=)
JP (2) JP7371019B2 (https=)
KR (1) KR20210014109A (https=)
CN (1) CN112424608A (https=)
AU (1) AU2019264996A1 (https=)
IL (1) IL278616B2 (https=)
WO (1) WO2019217916A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113842449A (zh) * 2021-09-08 2021-12-28 乐卫东 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3612566A4 (en) * 2017-04-21 2021-03-03 Implicit Bioscience Limited CD14 ANTAGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2025049671A1 (en) * 2023-08-30 2025-03-06 The Methodist Hospital Markers of amyotrophic lateral sclerosis survival and uses thereof
JPWO2025058005A1 (https=) * 2023-09-15 2025-03-20

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559795A1 (en) * 1990-11-30 1993-09-15 Monoclonetics Int Methods for the diagnosis of chronic lower back and cervical pain.
CA2467333A1 (en) * 2001-11-16 2003-06-12 Tennore M. Ramesh Methods for monitoring amyotrophic lateral sclerosis
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
CN1968962A (zh) * 2004-05-11 2007-05-23 持田制药株式会社 新型可溶性cd14抗原
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
US20120276114A1 (en) * 2009-11-18 2012-11-01 Universite D'aix-Marseille Ifn-gamma inhibitors in the treatment of motoneuron diseases
US20130230499A1 (en) * 2010-03-10 2013-09-05 Michal Eisenbach-Schwartz Cellular blood markers for early diagnosis of als and for als progression
CN103733068A (zh) * 2011-08-12 2014-04-16 三菱化学美迪恩斯株式会社 术后感染症的诊断方法
CN104011210A (zh) * 2011-10-11 2014-08-27 布里格姆及妇女医院股份有限公司 神经退行性病症中的microRNA
CN105102984A (zh) * 2012-12-28 2015-11-25 美迪恩斯生命科技株式会社 sCD14或它的片段或衍生物用于风险分级、诊断和预后的用途
CN106413721A (zh) * 2014-05-16 2017-02-15 纽拉尔图斯制药公司 用于治疗巨噬细胞相关病症的方法和组合物
WO2017103001A2 (en) * 2015-12-16 2017-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections
CN107003320A (zh) * 2014-11-25 2017-08-01 豪夫迈·罗氏有限公司 慢性肾脏疾病的快速进展的生物标志物
CN107683142A (zh) * 2015-04-02 2018-02-09 卫理公会医院 基于多孔硅微粒的癌症疫苗和增强抗肿瘤免疫性的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
ATE335072T1 (de) 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
CA2319828A1 (en) 1998-01-29 1999-08-05 Miller, Samuel High density arrays for proteome analysis and methods and compositions therefor
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US20010041349A1 (en) 2000-04-17 2001-11-15 Andrew Patron Protein expression system arrays and use in biological screening
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
AU2002220236A1 (en) 2000-11-09 2002-05-21 Bionova Pharmaceutials, Inc. A method for identifying the proteome of cells using an antibody library microarray
US7264967B2 (en) 2000-11-22 2007-09-04 Mochida Pharmaceutical Co., Ltd. Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding
EP1360490B1 (en) 2001-01-23 2011-12-21 President and Fellows of Harvard College Nucleic-acid programmable protein arrays
WO2003062444A2 (en) 2001-11-13 2003-07-31 Emory University Array systems and methods
EP1502102B1 (en) 2002-03-11 2009-01-14 caprotec bioanalytics GmbH Compounds and methods for analyzing the proteome
CA2754741C (en) * 2009-03-11 2019-02-12 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
US8465727B2 (en) 2009-10-06 2013-06-18 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for the diagnosis of ALS
WO2012004276A2 (en) * 2010-07-06 2012-01-12 Fondazione Telethon Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits
US11131676B2 (en) * 2016-02-25 2021-09-28 The Trustees Of Columbia University In The City Of New York Systemic immune activation and biomarkers of nonceliac wheat/gluten sensitivity
EP3612566A4 (en) 2017-04-21 2021-03-03 Implicit Bioscience Limited CD14 ANTAGONIST ANTIBODIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
AU2024238511A1 (en) * 2023-03-21 2025-10-02 Coya Therapeutics, Inc. Biomarkers of amyotrophic lateral sclerosis and uses thereof

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559795A1 (en) * 1990-11-30 1993-09-15 Monoclonetics Int Methods for the diagnosis of chronic lower back and cervical pain.
CA2467333A1 (en) * 2001-11-16 2003-06-12 Tennore M. Ramesh Methods for monitoring amyotrophic lateral sclerosis
CN1606694A (zh) * 2001-11-16 2005-04-13 Slil生物医学股份有限公司 监测和治疗肌萎缩性侧索硬化症的方法
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
CN1968962A (zh) * 2004-05-11 2007-05-23 持田制药株式会社 新型可溶性cd14抗原
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
US20120276114A1 (en) * 2009-11-18 2012-11-01 Universite D'aix-Marseille Ifn-gamma inhibitors in the treatment of motoneuron diseases
US20130230499A1 (en) * 2010-03-10 2013-09-05 Michal Eisenbach-Schwartz Cellular blood markers for early diagnosis of als and for als progression
CN103733068A (zh) * 2011-08-12 2014-04-16 三菱化学美迪恩斯株式会社 术后感染症的诊断方法
CN104011210A (zh) * 2011-10-11 2014-08-27 布里格姆及妇女医院股份有限公司 神经退行性病症中的microRNA
CN105102984A (zh) * 2012-12-28 2015-11-25 美迪恩斯生命科技株式会社 sCD14或它的片段或衍生物用于风险分级、诊断和预后的用途
CN106413721A (zh) * 2014-05-16 2017-02-15 纽拉尔图斯制药公司 用于治疗巨噬细胞相关病症的方法和组合物
CN107003320A (zh) * 2014-11-25 2017-08-01 豪夫迈·罗氏有限公司 慢性肾脏疾病的快速进展的生物标志物
CN107683142A (zh) * 2015-04-02 2018-02-09 卫理公会医院 基于多孔硅微粒的癌症疫苗和增强抗肿瘤免疫性的方法
WO2017103001A2 (en) * 2015-12-16 2017-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN LUNETTA, MD等: ""Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis"", 《JAMA NEUROLOGY》, vol. 74, no. 6, pages 1 *
S.D. SUSSMUTH, MD等: ""CSF glial markers correlate with survival in amyotrophic lateral sclerosis"", 《NEUROLOGY》, vol. 74, no. 12, pages 982 - 988 *
VALENTE, T 等: "C/EBPβ expression in activated microglia in amyotrophic lateral sclerosis", NEUROBIOLOGY OF AGING, vol. 33, no. 9, pages 2186 - 2199 *
叶学义 等: "基于张量的2D-PCA人脸识别算法", 计算机工程与应用, vol. 53, no. 06, pages 1 - 6 *
拱忠影;臧大维;: "肌萎缩侧索硬化生物标记物研究的新进展", 中华老年心脑血管病杂志, no. 03, pages 330 - 333 *
方鑫;吴艳;王芳;孙圣刚;: "CD14 mRNA、TLR4 mRNA在急性和亚急性MPTP帕金森病小鼠模型中的表达", 华中科技大学学报(医学版), no. 06, pages 775 - 779 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113842449A (zh) * 2021-09-08 2021-12-28 乐卫东 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用
CN113842449B (zh) * 2021-09-08 2024-02-23 乐卫东 枸杞糖肽在制备预防和/或治疗肌萎缩侧索硬化的药物中的应用

Also Published As

Publication number Publication date
IL278616B2 (en) 2025-02-01
JP2021523375A (ja) 2021-09-02
AU2019264996A1 (en) 2020-11-26
JP7371019B2 (ja) 2023-10-30
IL278616B1 (en) 2024-10-01
IL278616A (https=) 2021-01-31
WO2019217916A1 (en) 2019-11-14
KR20210014109A (ko) 2021-02-08
JP2023181255A (ja) 2023-12-21
US20210231686A1 (en) 2021-07-29
EP3791188A1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
US10877049B2 (en) Biomarkers for diagnosis and management of neuro-immunological diseases
JP2023181255A (ja) 疾病の予後と管理のための方法
JP7221264B2 (ja) Ｃｄ６結合パートナーの使用およびそれに基づく方法
RU2636032C2 (ru) Применение антитела i-3859 для выявления и диагностики рака
JP2009526020A (ja) 分泌型ｆｒｉｚｚｌｅｄ関連タンパク質４（ＳＦＲＰ−４）タンパク質結合剤
Sun et al. C-type lectin-like receptor 2: roles and drug target
US7709215B2 (en) Method for diagnosing and treating acute joint injury
JP2022528238A (ja) がん療法で使用するためのセマフォリン－４ｄアンタゴニスト
US20250297324A1 (en) Biomarkers of IL7R Modulator Activity
CN115104029A (zh) 用于检测和监测全身性炎症的非侵入性测定法
EP2795337B1 (en) Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
US11761963B2 (en) Biomarker signature for predicting tumor response to anti-CD200 therapy
EP2834640A1 (en) Cd247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs
JP2025529318A (ja) 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を有する患者における診断及び予後バイオマーカプロファイル
HK40115986B (en) Biomarkers of il7r modulator activity
HK40115986A (en) Biomarkers of il7r modulator activity
EP4508432A1 (en) Methods for the diagnosis and treatment of t-cell malignancies
WO2025088065A1 (en) Diagnosis and therapy of aml
JP2025537826A (ja) 抗ｓｉｒｐａ抗体についての効力予測バイオマーカー
AU2015265578A1 (en) Risk-stratification of B-precursor acute lymphoblastic leukemia patients
Tarabayeva et al. Modern approaches in personalized medicine. New stage of development of immunogenetics
Class et al. Patent application title: SCREENING METHODS TO IDENTIFY COMPOUNDS USEFUL IN THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY CONDITIONS Inventors: Reginald Christophe Xavier Brys (Mechelen, BE) Reginald Christophe Xavier Brys (Mechelen, BE) Sonia Dupont (Romainville, FR) Assignees: GALAPAGOS NV

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210226

WD01 Invention patent application deemed withdrawn after publication